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Abstract 
Background: CD20 is a B cell lineage–specific marker expressed by normal and leukemic B cells and targeted by 
several antibody immunotherapies. We have previously shown that the protein from a CD20 mRNA splice variant 
(D393‑CD20) is expressed at various levels in leukemic B cells or lymphoma B cells but not in resting, sorted B cells 
from the peripheral blood of healthy donors.
Results: Western blot (WB) analysis of B malignancy primary samples showed additional CD20 signals. Deep 
molecular PCR analysis revealed four new sequences corresponding to in‑frame CD20 splice variants (D657‑CD20, 
D618‑CD20, D480‑CD20, and D177‑CD20) matching the length of WB signals. We demonstrated that the cell spliceo‑
some machinery can process ex vivo D480‑, D657‑, and D618‑CD20 transcript variants by involving canonical sites 
associated with cryptic splice sites. Results of specific and quantitative RT‑PCR assays showed that these CD20 splice 
variants are differentially expressed in B malignancies. Moreover, Epstein–Barr virus (EBV) transformation modified the 
CD20 splicing profile and mainly increased the D393‑CD20 variant transcripts. Finally, investigation of three cohorts 
of chronic lymphocytic leukemia (CLL) patients showed that the total CD20 splice variant expression was higher in a 
stage B and C sample collection compared to routinely collected CLL samples or relapsed refractory stage A, B, or C 
CLL.
Conclusion: The involvement of these newly discovered alternative CD20 transcript variants in EBV transformation 
makes them interesting molecular indicators, as does their association with oncogenesis rather than non‑oncogenic 
B cell diseases, differential expression in B cell malignancies, and correlation with CLL stage and some predictive CLL 
markers. This potential should be investigated in further studies.
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Background
CD20 protein was highlighted in 1980 as a B lympho-
cyte–specific cell-surface antigen expressed in all stages 
of B cell ontogenesis except for early pro-B cells and 
plasma cells [1]. Despite no identified ligands, CD20 
functions were investigated, and studies assigned it a role 
in cell differentiation [2] and calcium flux pathways [3].
The anchorage within the membrane of the 33  kDa 
protein makes it a good candidate as an ion channel [3], 
especially when organized into tetramers [4]. Moreo-
ver, the presence of two extracellular loops allows for 
targeting by monoclonal antibodies (MAbs) to induce 
B cell depletion. The most well-known MAb is rituxi-
mab (RTX), which has greatly improved treatment of B 
cell malignancies [5], in association or not with chemo-
therapy [6]. After RTX, numerous other MAbs (such as 
obinutuzumab and ofatumumab) were subsequently 
developed to improve B cell depletion but also to treat 
RTX resistance to or escape from treatment [7].
CD20 is encoded by a MS4A family gene located on 
chromosome 11. Multiple transcription initiation sites 
have been identified, and the translated region of this 
gene is located between the third (193th nucleotide) 
and eighth exons (216th nucleotide), resulting in a cod-
ing sequence of 894  bp distributed into six exons [8]. 
Moreover, alternative splicing of the CD20 gene has been 
highlighted, occurring in the 5′ untranslated region and 
resulting in translation of three alternative CD20 mRNAs 
encoding the same protein in human B lymphocytes.
Alternative splicing remains a key process of pre-RNA 
maturation and allows an increase in protein transla-
tion and phenotype diversity [9]. Different patterns of 
splicing have been described, based on two families of 
regulatory proteins (constituting the spliceosome), the 
serine-rich (SR) and heterogeneous nuclear ribonucleo-
proteins (hnRNP) (for review, see [10]).
Aberrant splicing, caused by mutation in splice site 
sequences within cancer-related genes or in genes encod-
ing splicing regulation proteins [11], has a dominant 
role in tumor establishment, progression, and response 
to treatment [12]. Abnormal splicing mechanisms pro-
duce numerous cancer-associated alternatively spliced 
variants that could promote angiogenesis, invasion, and 
drug resistance, conferring a more aggressive tumoral 
profile [13]. These alternative variants are differen-
tially expressed in tumors [14] and thus may be used as 
diagnostic tools and prognostic markers [15]. Moreo-
ver, emerging treatments target new isoform proteins 
encoded from aberrant splicing [16] or modify splice 
site selection by oligonucleotide approaches to prevent 
abnormal splicing [17].
In oncohematology, numerous spliceosome gene 
mutations have been identified in chronic lymphocytic 
leukemia (CLL), myelodysplastic syndromes, and lym-
phomas; among the most well-known of these are those 
involving SF3B1, U2AF1, and SRSF2 [18–20]. Alternative 
splicing occurring in B cells could also be modified by 
Epstein–Barr virus (EBV) infection in which the BMLF1 
viral protein modifies STAT1 splicing after binding with 
the spliceosome component SRp20 [21] and thus may 
influence immortalization of target B cells.
We [22] and others [23] have identified novel alter-
native CD20 transcripts, fully matching the MS4A1 
sequence, except for 501 bp (from nucleotides 111–612, 
starting +1 of the ATG codon) flanked by the cryptic 
acceptor (AS) and donor (DS) splice sites. The resulting 
in-frame cDNA sequence encodes a truncated CD20 pro-
tein, called D393-CD20 (previously named ΔCD20 [22]), 
that is missing the major part of the transmembrane and 
extracellular domains, including the RTX epitope. Inter-
estingly, this protein has been observed in malignant 
or EBV-transformed B cells but not in peripheral blood 
mononuclear cells (PBMCs), bone marrow–derived mast 
cells, or plasmocytes from healthy donors.
Additional investigations of D393-CD20 protein 
expression by western blotting on different hematologic 
samples have allowed us to detect extra signals that we 
followed up in the current work, extended to autoim-
mune or EBV-infected samples. Our molecular analy-
sis has led to the description and characterization of 
new alternative CD20 transcripts that are differentially 
expressed in hematologic malignancies.
Results
Additional band signal is detected by c‑terminal CD20 
western blotting on blood samples collected from patients 
with hematologic malignancies
As expected, western blot analysis using a carboxy ter-
minus CD20 antibody targeted to circulating PBMCs 
from patients with B cell hematologic malignancies (CLL 
and NHL), CBL, B cell lines, or healthy donors revealed 
immunoreactive bands at 35  kDa corresponding to the 
full-length CD20 protein, indicating the presence of 
B lymphocytes in each sample (Fig.  1). As previously 
described, a band at 19  kDa, encoded by the CD20 
alternative transcript D393-CD20 [22], was detected on 
CLL (5/5) and NHL samples (3/3), as well as on leuke-
mic B cell lines (3/3). In contrast, the three CBL (without 
tumoral circulating B cells, as detected by B cell clonal-
ity analysis) and the four healthy donor samples were all 
negative for the 19 kDa band.
We clearly detected an unexpected additional immu-
noreactive band at approximately 27 kDa in all CLL and 
NHL samples. This band was also detected on MCL sam-
ples (data not shown). Surprisingly, this band was not 
detected on the three B cell lines. Moreover, western 
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blot allowed detection of a supplementary signal at 33 
and 17 kDa, respectively, close to the 35 kDa (full-length 
CD20 protein) or the 19 kDa (D393-CD20) bands.
Both CD20 homologous and truncated nucleotide 
sequences are identified in B cell lines
After RT-PCR of the full-length CD20 (fl-CD20) cod-
ing sequence, agarose gel electrophoresis allowed us to 
detect the expected two 894 and 393  bp PCR products 
corresponding respectively to the wt- and D393-CD20 
cDNA sequences. None of these visible amplified DNA 
fragments matched in size to products that could corre-
spond to a sequence encoding the 27 kDa or other addi-
tional signals.
All fl-CD20 PCR fragments between <894 and 100 bp 
in length, excluding the major 393  bp PCR product, 
were gel purified, TA cloned, amplified, and Sanger 
sequenced. Sequencing of more than 150 individual bac-
terial colonies allowed identification, in addition to the 
D393-CD20 sequence, of four new nucleotide sequences 
partially homologous to the wtCD20 reference nucleo-
tide sequence published in GenBank (NM152866.2) 
(Additional file 1: Figures S2 and S3). The four sequences 
are named according to the length of the nucleotide dele-
tion compared to the CD20 reference. Thus, D657-CD20, 
D618-CD20, D480-CD20, and D177-CD20 indicate dele-
tions of 237, 276, 414, and 717 bp, respectively.
All newly identified sequences code for in‑frame CD20 
transcript variants resulting in MS4A1 alternative splicing
Bioedit© alignments revealed that all of the new 
sequences matched perfectly at the 5′ and 3′ regions with 
the conservation of start and stop codons of the wtCD20 
whereas we detected a missing central area, generating a 
new sequence junction (Fig. 2a, b). A deeper analysis of 
the fusion sequences allowed highlighting of an alterna-
tive splicing phenomenon, bringing in a combination of 
cryptic or canonical DS or AS sites. Five splicing sites 
corresponded to canonical and three to cryptic sites, 
either DS or AS. Identification of the three cryptic-DS or 
cryptic-AS was confirm using the online splicing predic-
tion tools SplicePort Prediction [24] and ASSP Prediction 
[25] (Fig. 2b).
Based on [26], two patterns of splicing involving both 
canonical DS and AS were identified as exon or multiple 
exon skipping for D480- and D657-CD20, respectively. 
One splicing pattern involving cryptic and canonical sites 
was qualified as an alternative 3′ splice site (D618-CD20); 
lastly, two patterns (including the known D393-CD20) 
concerned alternative 5′ and 3′ cryptic splice sites. 
The characteristics of the splice variant transcripts 
are reported in Fig.  2b and summarized in Table  1. All 
sequences were in frame, and translation generated new 
amino acid fusion sequences (Fig. 2c).
Design of RT‑PCR and RT‑qPCR molecular tools allowed 
for specific detection and quantification of all newly 
identified spliced CD20 sequences
To study the presence of transcripts and their level of 
expression, we designed RT-PCR and RT-qPCR assays 
(Additional file 1: Figure S1). As shown in Fig. 3a, fl-CD20 
PCR allowed amplification of all CD20 alternative tran-
scripts from either genomic DNA or cDNA extracted or 
synthesized from transfected PG13 cell lines. Moreover, 
transcript-specific RT-PCR allowed detection specifically of 
the respective CD20 alternative transcripts without cross-
reactivity with the others, as shown when the target used 
was gDNA (Fig. 3b). Interestingly, D393spe-PCR amplified 
cDNA synthesized from ARN extracted from wt-, D657-, 
D480, and D393-CD20 cell lines. Positive signals detected 
with D177spe-PCR from all cell lines meant that all con-
structs could produce the D177-CD20 transcript.
Finally, RT-qPCR assays allowed specific detection with-
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Fig. 1 Western blot of CD20 expression. Western blotting of different samples collected from patients carrying B malignancies. CLL chronic lym‑
phoid leukemia, NHL non‑Hodgkin lymphoma, CBL cutaneous b lymphoma. Three B cell lines were included as well as samples from healthy donors 
as controls. β‑actin was used as a protein‑loading control. CD20 expression detection was performed using a C‑terminal polyclonal CD20 antibody. 
(*) showed additional bands excluding wt‑ and D393‑CD20 protein signals. Chemiluminescence time exposure was 5 min
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transcript variant to another. Reproducibility of all assays 
was assessed in seven independent experiments on four 
different B cell lines: Raji, Mec, Rec, and SKW6.1 (Fig. 3c). 
Standard deviations for values from each RT-qPCR for 
all four cell lines were (min–max) (0.52–0.8), (0.05–0.2), 
(0.1–0.52), (0.001–0.39), and (0.28–0.62), respectively, for 
D657-, D618-, D480-, D393-, and D177-CD20 PCR. Inter-
estingly, we noted that B cell lines resulting from different 
B cell malignancies present specific CD20 splicing profiles.
Reintroduction of intron sequences within the coding 
CD20 sequence confirms involvement of canonical DS or 
AS splicing sites in D657‑, D618, and D480‑CD20 splice 
variant transcription
To confirm that canonical sites associated with cryptic 
splicing sites may be involved in CD20 variant transcrip-
tion, as hypothesized from sequencing identification, 
some intron (3, 5, 6) sequences were used to generate 
artificial constructs carrying intron sequences within the 
wtCD20 coding sequence (Fig. 4a). D393- and D177-CD20 
were produced by all three constructs independently of 
the presence of canonical sites because splicing involved 
only cryptic DS and AS. However, reintroduction of int5 
alone in addition produced D618-CD20 transcripts. 
Dual reintroduction of int3 and 6 produced D480-CD20 
whereas the presence of int5 and 6 allowed expression of 
D657- and D618-CD20 mRNA (Fig. 4b).
All of these results confirmed that the cell spliceosome 
machinery can process the ex  vivo D480-, D657-, and 
D618-CD20 transcript variants by involving canonical 
sites associated with cryptic splice sites.
EBV transformation modifies the CD20 splicing profile 
and increases mainly D393‑CD20 variant transcripts
Among the four B cell lines, CD20 splicing quantification 
showed a higher and significant increase in D393-CD20 
variants in the EBV-transformed cell line SKW6.4. For 
this reason, the impact of EBV infection or transforma-
tion on CD20 splicing was investigated within different 
kinds of EBV samples.
Six EBV-transformed BLCLs were derived from the 
PBMCs of six healthy donors. As shown in Fig.  5a, total 
CD20 splicing was significantly increased in BLCL (3.4-
fold, p < 0.01) compared to their respective PBMCs. Sepa-
rate CD20 splice variant analysis revealed that increased 
total CD20 splices involved D657- and D618-CD20 but 
WT-CD20
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a Seq1 (D657) Seq2 (D618) Seq3 (D480) Seq4 (D393) Seq5 (D177)
Fig. 2 Characterization of new alternative CD20 transcript sequences. a Sequencing electropherograms showing junction areas resulting from 
alternative splicing number in brackets indicate size length deletion in nucleotides compared to the wtCD20 reference coding sequence. b Sche‑
matic alignment of newly identified sequences with wtCD20, reporting sequence deletions. Previously D393‑CD20 sequence is framed. Canonical 
(Ca) or cryptic (Cr) donor (DS) or acceptor (AS) splice sites are reported as well as their nucleotide position from +1ATG nucleotide (in italics)
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mainly and statistically significantly D393-CD20 (110 
time, p < 0.001). D393-CD20 represented the major part 
(76.5  %) of the total CD20 splice increase compared to 
both D657- and D618-CD20 (23.4 %).
In contrast, total CD20 splicing did not vary sig-
nificantly either for IMN samples compared to healthy 
PBMCs (Fig.  5b) or for EBV-reactivated samples after 
allograft (Fig. 5c), although we noted an increase in D657 
and D618-CD20 splicing. Interestingly, D393-CD20 tran-
scripts did not increase in these EBV-infected cases com-
pared to EBV-transformed cell lines.
CD20 splice variant profile expression can discriminate B 
cell malignancies
Using the different CD20 variant profiles in the different 
B cell lines, Raji, Mec, Rec, and SKW6.1 (Fig. 3c), derived 
from different hematologic diseases (respectively, CLL, 
Burkitt lymphoma, MCL, B lymphoblastoid), we inves-
tigated the RT-qCPR expression of the different CD20 
variant transcripts in different B cell malignancies. The 
percentage of total alternative CD20 transcripts from all 
four B cell lines but also from the primary cells of FLs and 
DLBCLs were significantly different from healthy PBMCs 
(p = 0.01 and <0.01 respectively) (Fig. 6a).
When analyzed separately, D657 was found to be 
mainly involved in the increase of total CD20 splicing 
(81.93 %) whereas D618 and D393 represented, respec-
tively, 7.04 and 10.66 % of the increase in FL. In contrast, 
in DLBCLs, the increase was due in part to D657-CD20 
(43.87  %) but also to D393-CD20 (40.26  %) whereas 
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Fig. 3 Alternative CD20‑transcripts, putative proteins and junction characterization. a Schematic representation of CD20 variant coding transcripts. 
Transmembrane domains (TM) are positioned on the linear N‑ter/C‑ter protein, as well as position of the main clinical anti‑CD20 antibody epitopes. 
Rituximab (gray line), Ofatumumab (blue line) and Obinutuzumab (red line). Schematic representation of antibody recognition on the putative 
CD20 variant‑proteins. AA position is provided and numbered from the first ATG (Met) start codon. b Schematic reconstitution of amino acidic (AA) 
junction area after splicing involving canonical (closed boxes) or cryptic (open boxes) splice. AA sequence flanking junction is provided as well as AA 
position
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Relevance of alternative CD20 splice variant quantification 
within three different CLL patient cohorts
We took advantage of the availability of CLL samples 
from three different cohorts of patients (two collected 
at diagnosis and one at relapse): routinely collected CLL 
patient samples (50.8–49.1 % stages A–B/C respectively) 
for routine diagnostic analysis (CHU Toulouse, France, 
n =  70); CD19-positive B cells purified from diagnostic 
stage B and C (65.5 and 34.5 %, respectively) CLL samples 
from elderly patients (>65 years, median 71.2) (CLL2007-
SA trial [27], n =  54); and samples from relapsed stage 
A, B, or C (mainly stages B and C, 88.7 %) active-disease 
patients (CLL01 BOMP clinical trial, n = 70). Character-
istics of CLL populations are given in Additional file  1: 
flCD20-PCR
gDNA
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Fig. 4 RT‑PCR and RT‑qPCR assays of different CD20 transcript variants. a Full‑length PCR (fl‑CD20) allowed amplification of all CD20 alternative 
transcripts. Genomic DNA (gDNA) from wild‑type PG13 (ø) and PG13 transfected by wtCD20, D657‑, D618‑, D480‑, D393‑, or D177‑CD20 were 
amplified using primers specific for the 5′ (start codon) and 3′ (stop) CD20 gene regions, common to the six transcripts. H2O was used as negative 
control (−), and the plasmid carrying the specific CD20 variant was added to the positive control (+). b CD20 variant‑specific PCR was designed to 
amplify each alternative transcript specifically. c Proportion (in %) of each CD20 variant transcript in four different B cell lines. Means and SD calcu‑
lated from seven independent experiments of RT‑qPCR quantification
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Table S2. Considering the percentage in CLL2007-SA, 
the median of total CD20 splicing (1.26 ±  1.23  %) was 
significantly higher than in routine CLL (0.65  ±  0.5  %, 
p < 0.02) or BOMP (0.76 ± 1.02 %, p < 0.001) (Figs. 7a, 
8). The increase was mainly due to the D657- and 
D618-CD20 transcript variants and to a lesser degree to 
the D393-CD20 transcripts (Fig. 7b).
Discussion
We have previously identified a novel alternative CD20 
transcript, fully matching the MS4A1 sequence, except 
for a 501-bp region flanked by cryptic AS and DS [1]. The 
resulting in-frame cDNA sequence encodes a truncated 
CD20 protein revealed by a C-terminal CD20 polyclonal 
antibody. Interestingly, this protein has been observed in 
malignant or EBV-transformed B cells but not in PBMCs, 
bone marrow–derived mast cells, or plasmocytes from 
healthy donors.
Detection of unexpected additional western blot signals 
with an anti-carboxy terminus CD20 antibody led us to 
conduct a deep molecular analysis to characterize poten-
tial transcripts that could match the protein signal. Start-
ing from nucleic acid material extracted from B cell lines 
or, interestingly, from primary samples of patients with B 
cell hematologic diseases such as CLL, MCL, or DLBCL, 
we identified and characterized more precisely, in addi-
tion to the D393-CD20, four additional CD20 splice 
variants. Two of these variants are the result of exon 
skipping (D657- and D480-CD20), and the other two 
result from the use of alternative splice sites: a canoni-
cal DS and a cryptic AS for D618-CD20 and two cryptic 
splice sites for D177-CD20, by previously well-described 
mechanisms [10]. In addition to the D393-CD20 tran-
script, Small et al. [23] have already detected the D618- 
and D657-CD20 transcripts only in lymphoblastoid B 
cell lines. In the current work, we detected expression 
of these two transcripts in primary samples of human 
B cell diseases and reported for the first time two novel 
additional D480- and D177-CD20 transcripts. We also 














Fig. 5 Intron reintroduction within the wtCD20 coding sequence. a Schematic representation of position of alternative splice sites (ASS) in the 
wtCD20 coding sequence and within the constructs after reintroduction of introns 5 (CD20‑int5), 3 and 6 (CD20‑int3–int6), and 5 and 6 (CD20‑int5–
int6). ASS positions for D657 (closed circle), D618 (closed star), D480 (closed square), D393 (*), and D177 (closed triangle) are indicated. Gray and black 
symbols represent canonic and cryptic splice sites, respectively. b Specific RT‑PCR detection of different CD20 variants in transfected HT1080 cell 
lines with different constructs. Plasmid was used as positive control and untransfected HT1080 cells as negative (ф). Raf amplification PCR was used 
as control for the cDNA synthesis
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associated with cryptic splice sites that produce these 
transcripts. Although it should be formally demon-
strated, except for D177, the lengths of the D393, D618-, 
D657-, and D480-CD20 transcripts matched the immu-
noreactive bands on western blot.
We designed quantitative molecular tools for study-
ing alternative CD20 transcript expression in different 
B autoimmune, malignant B diseases or EBV-infected 
samples.
The comparison of splicing profiles revealed a more 
important CD20 alternative splicing in B diseases com-
pared to healthy donors, suggesting a splicing deregula-
tion in these pathologies.
Whereas a slight increase of CD20 alternative splic-
ing was detected in CBCL, LZM, MM, and some CLL 
samples, a significantly higher amount of alternative 
transcripts was observed in FL, HG-NHL, and EBV-
transformed B cell lines. In all cases, the increase com-
pared to healthy donors results from a higher proportion 
of D618- and D657- CD20 transcripts. In addition, this 
increase is associated with a D393-CD20 expression 
induction in lymphomas (FL, DLBCL, Burkitt and MCL) 
and EBV transformation. Interestingly, in autoimmune 
diseases (rheumatoid arthritis and pemphigus), we never 
detected D393-CD20 transcripts [28, 29]. These observa-
tions suggest a splicing deregulation during oncogenesis 
leading to D393-CD20 expression, which could be an 
interesting molecular marker of B malignancies.
From another side, the slight increase of D657- and 
D618-CD20 expression could be the result of splicing 
deregulation associated with an enhanced proliferation 
and activation [30] during cancer but also during autoim-
mune disease and virus infection [31].
Increase of D393-CD20 occurs mainly in post-germi-
nal center (GC) lymphomas (FL, Burkitt, and DLBCL). 
In GC, BCR maturation requires activation-induced 
cytidine deaminase (AID) intervention to introduce mis-
matches, which are then repaired by a mismatch repair 
complex. This process is known to be responsible for 





































































































































Fig. 6 CD20 splicing quantification of EBV samples. Quantification by RT‑qPCR of total (TS) and specific CD20 splice variants of a EBV‑transformed 
B lymphoblastoid cell line, BLCL (closed triangle), compared to their respective PBMCs (closed circle); n = 6. b Infectious mononucleosis (IMN, closed 
rhombus, n = 4); c EBV‑reactivated samples (EBV load increase >2 Log/ml. EBVr, inverted closed triangle, n = 10) after allograft compared to heathy 
PBMCs (closed circle, n = 6). (*) and (**) are the results of X2 tests with p < 0.02 and p < 0.002, respectively. CD20 transcript quantification within 
PBMCs reported as reference in all total or specific splicing quantification analyses. d Proportion (in %) of each CD20 transcipt variant in EBV samples 
in comparison with PBMC
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also disturb splicing. Indeed, interactions and associa-
tions have been identified between AID and splicing fac-
tor SnRNPs such as U2AF65 [32], PTB2, and SRSF2 [33]. 
This link may explain in part how the AID activation 
pathway could lead to deregulation of splicing factors 
that disturb CD20 splicing, thus producing alternative 
CD20 variant expression in post-GC lymphomas. In 
post GC CLL, the fact that D393-CD20 increase was not 
observed may be explained by a lower AID expression 
[34] and activation.
Splicing pattern of immortalized B cell after EBV virus 
infection (DBCL) revealed a significantly greater increase 
in total CD20 splice variants, mainly because of an 
expression of D393-CD20. Interestingly, CD20 splicing 
was not statistically increased in IMN or in reactivated 
EBV samples: although we noted an increase of D618- 
and D657-, no D393-CD20 expression was measured, 
contrasting with DBCL. These results suggested a CD20 
splicing modulation caused by an oncogenesis process 
rather than viral infection itself. This strengthens the 
hypothesis of an association between D393-CD20 and 
oncogenesis. It is known that the SM (Mta, EB2, BMLF1) 
EBV protein, a viral oncogenic nuclear protein bound to 
RNA, influences RNA stability, splicing, nuclear export, 
and translation. This influence facilitates virus replica-
tion and persistence in  vivo [35]. SM protein is associ-
ated with three splice regulators, SF2/ASF (SRSF1), 9G8 
(SRSF7), and SRp20 (SRSF3), and antagonizes SRSF3 
[36]. Thus, the SM EBV protein may be an actor that reg-
ulates CD20 cellular gene expression at the level of alter-
native splicing.
This work shows a deregulated expression of CD20 
variant transcripts in B malignancies that may be use-
ful as a molecular marker to study splicing patterns in 
order to better classify malignancies, predict resolu-
tion of disease, or monitor treatment [12]. In this way, 
we took advantage of the availability of sf3b1 mutational 
status of the BOMP relapsed CLL cohort to evalu-
ate if there is a correlation with CD20 splicing. CLL 
disease is an interesting model because mutations of 
sf3b1, which encode a critical component of the splic-




















































































































































































Fig. 7 RT‑qPCR quantification of all CD20 splice variants within B cell malignancies. Quantification by RT‑qPCR of total a or specific b, c CD20 splice 
variants in four B cell lines, in different B cell malignancies, compared to PBMCs from healthy donors (n = 6). c Proportion (in %) of each CD20 
transcript variant in different B cell malignancies. CBCL cutaneous B cell lymphomas (n = 5), FL follicular lymphoma (n = 5), DLBCL diffuse large B cell 
lymphoma (n = 5), MCL mantle‑cell lymphoma (n = 19), MZL marginal zone lymphoma (n = 12), MM multiple myeloma (n = 3). (*) and (**) are the 
results of X2 tests with p = 0.01 and p < 0.001, respectively, compared to PBMC samples
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fludarabin-refractoriness [37]. Interestingly, we noticed 
that patient group with more cd20 alternative splic-
ing correspond to those with higher sf3b1 mutation 
frequency (data not shown). These results should be 
confirmed with other CLL cohorts, and a potential cor-
relation with other gold standard biomarkers of CLL 
should be investigated. Moreover, a significant differ-
ence of total CD20 splicing between the 2 CLL cohorts 
at diagnosis (routine CLL cohort vs elderly CLL2007-
SA, respectively 50 and 11 % stage A) could make this 
marker an indicator of the stage of the disease progres-
sion, which could be useful for CLL stratification.
Alternative CD20 splicing may have consequences on 
CD20 protein function that may influence BCR/CD20 
cell signaling and finally B cell functions. We previously 
described that D393-CD20 transcript encoded a trun-
cated CD20 protein [22]. Using CD20 immunoprecipita-
tion with an antibody targeting the extracellular domain 
followed by western blot with the C-terminal CD20 
specific antibody, we have already demonstrated that 
D393-CD20 protein is associated with wtCD20. Accord-
ing to the predicted sizes of other putative proteins, they 
could also be associated with wtCD20 since the sizes 
match additional bands observed on western blot (Addi-
tional file 1: Figure S4). Subcellular division of transfected 
cells with the D393-CD20 coding sequence revealed that 
the variant protein is found mainly in the membrane 
fraction, although the main part of the transmembrane 
coding sequence is missing. This result strongly suggests 
an association between wtCD20 and D393-CD20 pro-
tein. Finally, lipid raft isolation showed the presence of 
D393-CD20 and wtCD20 already within the lipid rafts. 
All of these observations suggest a possible involvement 
of proteins encoded by cd20 alternative variants in BCR 










































































































































































































































































































































































































Fig. 8 RT‑qPCR quantification of total or specific CD20 splice variant expression within three different CLL sample cohorts. Quantification by RT‑
qPCR of total a or specific b, c CD20 splice variants in three cohorts of patients: CLL patient samples collected during routine diagnosis (50.8–49.1 %, 
stages A–B/C, respectively) (CHU Toulouse, France, n = 70); CD19‑positive B cells purified from diagnostic stages B and C (65.5 and 34.5 %, respec‑
tively); and CLL samples from elderly patients (>65 years; median, 71.2) (CLL2007‑SA trial (n = 54) or from patients with relapsed stages A, B, or C 
(mainly stages B and C for 88.7 %) with active disease (CLL01 BOMP clinical trial, n = 70). c Proportion (in %) of each CD20 transcript variant in differ‑
ent CLL cohorts. (*) and (**) are the results of X2 tests with p = 0.01 and p < 0.001, respectively, compared to PBMC samples
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Another consequence of the CD20 splicing is the pro-
duction of in-frame mRNA that could be translated into 
new proteins and could thus participate in the tumoral 
edition by generating neo-epitopes that could be targeted 
in anti-tumoral vaccine strategies [39, 40]. Concerning 
CD20 alternative splice variants, we have demonstrated 
that the 20mer D393-CD20 peptide spanning the splic-
ing site might be targeted by the immune system, and 
we have shown that D393-CD20—specific CD4 Th1 
clones could directly recognize malignant B cell lines 
and kill autologous lymphoma B cells, indicating that 
D393-CD20—derived epitopes are naturally processed 
and presented on tumor cells [41]. Additional CD20 
alternative variants may also be new tumoral antigens 
that could be targeted by a redirected immune system, 
such as transgenic T cell receptors.
These observations may be useful for the development 
of new immunotherapies applied to patients refractory 
to conventional (chemotherapy) or targeted treatments 
(anti-CD20, Ibrutinib, iBTK).
In conclusion, the discovery of new alternative CD20 
transcript variants makes them of interest as molecular 
indicators to investigate in further studies, particularly 
given the involvement of some of them in EBV transfor-
mation, their association with oncogenesis rather than 
non-oncogenic B diseases, their differential expression in 
B malignancies, and correlation with CLL stage and some 
predictive CLL markers. Overall, these findings need to 
be confirmed by larger prospective trials in order to fully 
validate CD20 transcript variant as molecular markers of 
oncogenesis.
Methods
Patients, biological samples, and cell lines
Master cell banks of human and mouse cell lines were 
prepared from cells from the DSMZ or ATCC cell banks. 
Working cell cultures were then established, and cells 
were cultured in RPMI 1640 or DMEM with 10  % fetal 
calf serum. STR profiling identification was performed 
regularly.
Peripheral blood samples were selected from cases of 
hematologic B cell disease: B-CLL, follicular lymphoma 
(FL), mantle cell lymphoma (MCL), diffuse large B cell 
lymphoma (DLBCL) and cutaneous B cell lymphoma 
(CBCL), multiple myeloma (MM), marginal zone lym-
phoma, non-Hodgkin lymphoma (NHL), or autoimmune 
disease (rheumatoid arthritis), as well as infectious mon-
onucleosis (IMN). In addition, EBV-reactivated samples 
collected from renal, lung, or hematopoietic allografts 
were screened. Samples were collected from diagnostic 
assessment or clinical trials or from a blood bank for the 
healthy PBMCs.
EBV-derived B lymphoblastoid cell lines (BLCLs) were 
established from healthy donor PBMCs. PBMCs were 
transformed with EBV supernatant in X-VIVO medium 
with cyclosporine A at 1 µg/ml for 2 days and maintained 
in culture for at least 10 days, until an immortalized B cell 
line was obtained.
CLL samples were collected from three different 
cohorts of patients: PBMCs collected at diagnosis for 
routine analysis (CHU Toulouse, France); CD19+ immu-
nomagnetic-purified B cells (whole human blood CD19 
MicroBeads, Miltenyi Biotec) from CLL patient sam-
ples, stage B and C, included within the CLL2007-SA 
(for elderly patients older than 65  years); and patients 
included in the ICLL01 BOMP clinical trial (relapsed or 
refractory CLL stages A, B, or C with active disease or 
after 1–3 previous lines including at least one line with 
fludarabine), both initiated by the GOELAMS/GCFLLC-
MW intergroup. Written informed consent was obtained 
according to institutional protocol and approbation of 
the Ethic Committee (Comité de protection des person-
nes: CPP-Est, France).
Western blotting
Cells were lysed in sample buffer (2  % sodium dodecyl 
sulfate (SDS) in 125  mM Tris HCl, pH 6.8). An equiva-
lent protein amount, extracted from 1 × 107 to 8 × 107 
cells, was separated by electrophoresis on 12 % SDS–pol-
yacrylamide gels and transferred to Polyvinylidene dif-
luoride (PDVF) membranes (GE Healthcare).
Blots were then blocked for 1 h in 6 % milk before incu-
bation with specific antibodies as follows: rabbit anti-
human CD20 specific to the COOH-terminal region [22] 
(Thermo Scientific) and rabbit anti-actin (#8457L, Cell 
Signaling). Blotted proteins were detected and quantified 
on a bioluminescence imager and BIO-1D advanced soft-
ware (Vilber-Lourmat) after blots were incubated with a 
horseradish peroxidase–conjugated appropriate second-
ary antibody (Beckman Coulter).
Molecular studies: RNA isolation, reverse transcription, 
cloning, real‑time quantification, and Sanger cycle 
sequencing
Total RNA was extracted using the RNeasy Total RNA 
Isolation kit (Qiagen, Courtaboeuf, France), following 
manufacturer protocols. One microgram of total RNA 
was used as template for cDNA synthesis performed 
using a high-capacity RNA to cDNA kit (Applied Biosys-
tem, Courtaboeuf, France).
Genomic DNA was extracted using a DNeasy blood 
or tissue kit (Qiagen, Courtaboeuf, France) or the salt-
ing out method. Briefly, cells were lysed by TES buffer 
supplemented by SDS 20  % and proteinase K 0.5  mg/
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ml. Proteins were then precipitated in a saturated NaCl 
solution and centrifuged, and DNA then was precipitated 
using ethanol.
Qualitative RT-PCR was performed using the MyTaq 
DNA polymerase ready-to-use master mix (Bioline, 
France) and specific primers. PCR products were ana-
lyzed by agarose gel electrophoresis followed by ultra-
violet detection. When useful, PCR products were gel 
purified, cloned within pCR® 2.1-TOPO® TA vector 
(Life Technologies), and Sanger forward and reverse 
sequenced using M13 primers. Purified sequencing prod-
ucts were run on an ABI-3130 DNA analyzer and ana-
lyzed using sequencing analysis v5.2 software (Applied 
Biosystems). Sequences were aligned against the wild-
type (wt)CD20 coding sequence using the Bioedit v7.1 
software.
Quantitative RT-PCR (RT-qPCR) was performed 
using splice variant–specific primers and bi-fluorescence 
probes. cDNA was amplified with TaqMan Universal 
Master Mix with UNG (Applied Biosystem, Courtaboeuf, 
France) using a standard two-step amplification program 
(10 s at 95° and 1 min at 60°).
CD20 variant transcript copy number was assessed 
by RT-qPCR against a plasmid dilution curve. All PCR 
samples were normalized to ABL copy number. The pro-
portion of each CD20 transcript variant was calculated 
against all CD20 isoforms.
PCR conditions, sizes of PCR products, and names and 
sequences of primers are described in Additional file  1: 
Table S1. Schematic localizations of all PCR primers and 
bi-fluorescent probes are provided in Additional file  1: 
Figure S1.
Cell transfection and packaging cell line production
The wtCD20 coding sequence was first cloned into a 
pcDNA3.1-GFP (green fluorescent protein) mamma-
lian expression vector. To restore canonical splice sites 
within the cDNA coding sequence, intron 5 (int5) was 
previously reintroduced into pcDNA3.1-GFP-wtCD20 
to generate pcDNA3.1-GFP-int5-CD20, theoretically 
producing D618-CD20 transcripts. Intron 6 (int6) was 
then inserted into pcDNA3.1-GFP-int5-CD20 to gen-
erate pcDNA3.1-GFP-int5– and 6-CD20–expressing 
D657-CD20 transcripts. Finally, reintroduction of introns 
3 (int3) and 6 within the wtCD20 sequence allowed 
expression of D480-CD20 mRNA from pcDNA3.1-GFP-
int3 and the 6-CD20 vector. All of these vectors were 
amplified into JM105 bacteria. The HT1080 cell line 
was then transfected by these vectors using the Lipo-
fectamine transfection kit (Life Technologies) to produce 
transiently expressing cell lines.
In addition to the D393-CD20 packaging cell line, pre-
viously produced, wtCD20, D657-CD20, and D618-CD20 
coding sequences were inserted into the retroviral 
pBABE-GFP vector (Addgene, UK). The PG13 packag-
ing cell line was transfected by the pBABE-GFP-wtCD20, 
pBABE-GFP-D657-CD20, and pBABE-GFP-D618-CD20 
vectors using the Lipofectamine transfection kit (Life 
Technologies). Supernatants were then collected at 48, 
72, and 96  h to produce HT1080-transduced cells, cul-
tured and selected in puromycin-containing medium. 
The percentage of stably transduced cells was controlled 
by assessing GFP expression by flow cytometry.
Splice site prediction and statistical computational analysis
Splicing sites were identified using online splice site pre-
diction tools such as SpliceProt prediction [24] (http://
www.spliceport.org.) or ASSP Prediction [25] (http://
wangcomputing.com/assp/). Statistical analysis was per-
formed using the Χ2 test.
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Additional file 1: Table S1. Table of primers used for wtCD20 and 
transcript variant detection (RT‐PCR) as well as realtime PCR quantification 
(RT‐qPCR). Specific annealing temperature and PCR product size in bp are 
given for RT‐PCR. ABL PCR was used for control gene expression quan‑
tification. Table S2: Characteristics (n, genders, Binet score, biological 
parameters, mutational status) of the three CLL patient cohorts. NA: not 
available. Figure S1: Schematic representation of wtCD20 and transcript 
variants. Qualitative PCR primers as well as quantitative primers forward 
(→) and reverse (←) and bi‐fluorescent probes (•–•) are localized up and 
down, respectively, on the different transcripts. Figure S2: wtCD20 cod‑
ing sequence (NCBI‐GenBank NM152866.2) given as reference as well as 
D393‐CD20, previously described [22] shown in blue. The 4 new identified 
coding sequences of the CD20 alternative transcripts are also in blue. 
Figure S3: Alignment of the newly discovered sequences against the 
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immunoprecipitation (IP) was performed using an antibody specific 
to an extracellular epitope of human CD20 (#302302, Biolegend) and 
western blot detection with the cterminal human CD20 Rabbit Polyclonal 
antibody (#E2562, Thermofischer) b/Subcellular fractions [Membrane 
(M), Cytoplasm (C), Nucleus (N)] obtained from 293 cells transfected with 
a lentiviral vector pFIV‐D393‐CD20 or pFIV‐wtCD20 were subjected to 
western blot analysis using c‐terminal CD20 or actin (for protein loading 
control) antibodies. Blotted proteins were detected and quantified on a 
bioluminescence imager with BIO‐1D advanced software (Wilber‐Lour‑
mat) after incubation of blots with a horseradish peroxidase–conjugated 
appropriate secondary antibody (Beckman Coulter). c/Lipid raft isolation 
by ultra‐centrifugation on sucrose density gradient. Fractions 1 to 4 (10 % 
to 40 % of sucrose density) respectively harvested after centrifugation 
were subjected to c‐terminal anti‐CD20 western blotting. Actin and Flotil‑
lin‐2 antibody staining was used as protein‐loading and lipid‐raft control, 
respectively.
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